Abstract
The present study emphasizes the molecular interactions between human brain acetylcholinesterase (AChE) and the natural ligand Huperzine-B and its comparison to ‘AChE-Tolserine interactions’. Docking between Huperzine-B and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of Huperzine-B within the ‘catalytic site’ of AChE to permit docking. However, docking of Tolserine to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of Huperzine-B. Scope still remains in the determination of the three-dimensional structure of AChE-Huperzine-B complex by X-ray crystallography to validate the described data. Furthermore, this study confirms that Huperzine-B is a more efficient inhibitor of human brain AChE compared to tolserine with reference to Ki and ΔG values.
Keywords: Acetylcholinesterase, autodock4.2, hydrophobic interactions, catalytic site.
CNS & Neurological Disorders - Drug Targets
Title:Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach
Volume: 13 Issue: 3
Author(s): Aftab Alam, Sibhghatulla Shaikh, Syed S. Ahmad, Mohammad A. Ansari, Shahnawaz Shakil, Syed M.D. Rizvi, Shazi Shakil, Mohammad Imran, Mohammad Haneef, Adel M. Abuzenadah and Mohammad A. Kamal
Affiliation:
Keywords: Acetylcholinesterase, autodock4.2, hydrophobic interactions, catalytic site.
Abstract: The present study emphasizes the molecular interactions between human brain acetylcholinesterase (AChE) and the natural ligand Huperzine-B and its comparison to ‘AChE-Tolserine interactions’. Docking between Huperzine-B and AChE was performed using ‘Autodock4.2’. Hydrophobic interactions and hydrogen bonds both play an equally important role in the correct positioning of Huperzine-B within the ‘catalytic site’ of AChE to permit docking. However, docking of Tolserine to AChE is largely dominated by hydrophobic interactions. Such information may aid in the design of versatile AChE-inhibitors, and is expected to aid in safe clinical use of Huperzine-B. Scope still remains in the determination of the three-dimensional structure of AChE-Huperzine-B complex by X-ray crystallography to validate the described data. Furthermore, this study confirms that Huperzine-B is a more efficient inhibitor of human brain AChE compared to tolserine with reference to Ki and ΔG values.
Export Options
About this article
Cite this article as:
Alam Aftab, Shaikh Sibhghatulla, Ahmad S. Syed, Ansari A. Mohammad, Shakil Shahnawaz, Rizvi M.D. Syed, Shakil Shazi, Imran Mohammad, Haneef Mohammad, Abuzenadah M. Adel and Kamal A. Mohammad, Molecular Interaction of Human Brain Acetylcholinesterase with a Natural Inhibitor Huperzine-B: An Enzoinformatics Approach, CNS & Neurological Disorders - Drug Targets 2014; 13 (3) . https://dx.doi.org/10.2174/18715273113126660163
DOI https://dx.doi.org/10.2174/18715273113126660163 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of NMR Spectroscopy in Medicinal Chemistry and Drug Discovery
Current Topics in Medicinal Chemistry Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Recent Progress in Cerebrovascular Gene Therapy
Current Neurovascular Research Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Resveratrol Protects β Amyloid-Induced Oxidative Damage and Memory Associated Proteins in H19-7 Hippocampal Neuronal Cells
Current Alzheimer Research Treatment of Cognitive Impairment in Schizophrenia: Potential Value of Phosphodiesterase Inhibitors in Prefrontal Dysfunction
Current Pharmaceutical Design Mitochondrial Dysfunction and Alzheimers Disease
Current Alzheimer Research Effects of Resveratrol and Other Polyphenols on the Most Common Brain Age-Related Diseases
Current Medicinal Chemistry Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities
Current Drug Targets Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry Anti-TNF Treatment in Rheumatoid Arthritis
Current Pharmaceutical Design Programmed Cell Death Mechanisms in Neurological Disease
Current Molecular Medicine Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology [<sup>18</sup>F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Current Alzheimer Research Quantitative and Mechanistic Studies of Aβ Immunotherapy
CNS & Neurological Disorders - Drug Targets Mechanism of CNS Drugs and their Combinations for Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry The NMDA Receptor/Ion Channel Complex: A Drug Target for Modulating Synaptic Plasticity and Excitotoxicity
Current Pharmaceutical Design Vascular effects of flavonoids
Current Medicinal Chemistry